Literature DB >> 25990485

Influence of the previous use of β-blockers on the early clinical course of acute coronary syndromes.

Juan Carlos Garcia-Rubira1, Manuel Almendro-Delia2, Manuel Calvo-Taracido2, Emilia Blanco-Ponce2, Pablo Bastos-Amador2, Antonio Reina-Toral3, Roman Calvo-Jambrina2, José Maria Cruz-Fernández2, Angel Garcia-Alcántara4, Rafael Hidalgo-Urbano2.   

Abstract

Recent studies have recently questioned the current role of β-blockers in myocardial infarction. Our purpose is to analyze the influence of the previous use of β-blockers on the early course of patients admitted because of acute coronary syndrome (ACS). We analyzed the data of 37.359 patients included in the ARIAM-Andalucia Registry. Of them, 7759 (20.8%) were previously receiving β-blockers. BB patients were older, more often female, had more risk factors and vascular disease, and less often had an ST-elevation myocardial infarction. In the unadjusted analysis, BB patients less often had ventricular fibrillation or atrioventricular block, and more often a Killip classification >1, and no difference of in-hospital mortality (5.7 vs 5.6%). After logistic regression analysis and propensity score matching, no differences in complications or mortality (odds ratio 0.997, 95% confidence interval 0.882-1.128) were found in relationship to previous β-blockers. In conclusion, we find that the previous administration of β-blockers is not an independent predictor of the early prognosis of ACS.

Entities:  

Keywords:  Acute coronary syndrome; Myocardial infarction; Outcomes; β-Blockers

Mesh:

Substances:

Year:  2015        PMID: 25990485     DOI: 10.1007/s11739-015-1251-3

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  32 in total

1.  beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction.

Authors:  S L Nuttall; V Toescu; M J Kendall
Journal:  BMJ       Date:  2000-02-26

Review 2.  Expert consensus document on beta-adrenergic receptor blockers.

Authors:  José López-Sendón; Karl Swedberg; John McMurray; Juan Tamargo; Aldo P Maggioni; Henry Dargie; Michal Tendera; Finn Waagstein; Jan Kjekshus; Philippe Lechat; Christian Torp-Pedersen
Journal:  Eur Heart J       Date:  2004-08       Impact factor: 29.983

Review 3.  Cardiovascular protection using beta-blockers: a critical review of the evidence.

Authors:  Sripal Bangalore; Franz H Messerli; John B Kostis; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2007-07-30       Impact factor: 24.094

4.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

Review 5.  Usefulness of Beta blockade in contemporary management of patients with stable coronary heart disease.

Authors:  David E Winchester; Carl J Pepine
Journal:  Am J Cardiol       Date:  2014-08-27       Impact factor: 2.778

6.  Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials.

Authors:  Sripal Bangalore; Harikrishna Makani; Martha Radford; Kamia Thakur; Bora Toklu; Stuart D Katz; James J DiNicolantonio; P J Devereaux; Karen P Alexander; Jorn Wetterslev; Franz H Messerli
Journal:  Am J Med       Date:  2014-06-11       Impact factor: 4.965

7.  Rationale and design of a double-blind, multicenter, randomized, placebo-controlled clinical trial of early administration of intravenous β-blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention: EARLY β-blocker administration before primary PCI in patients with ST-elevation myocardial infarction trial.

Authors:  Vincent Roolvink; Saman Rasoul; Jan Paul Ottervanger; Jan-Henk E Dambrink; Erik Lipsic; Iwan C C van der Horst; Bart de Smet; Elvin Kedhi; A T Marcel Gosselink; Jan J Piek; Vicente Sanchez-Brunete; Borja Ibanez; Valentin Fuster; Arnoud W J Van't Hof
Journal:  Am Heart J       Date:  2014-07-28       Impact factor: 4.749

8.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

Authors:  Sripal Bangalore; Gabriel Steg; Prakash Deedwania; Kevin Crowley; Kim A Eagle; Shinya Goto; E Magnus Ohman; Christopher P Cannon; Sidney C Smith; Uwe Zeymer; Elaine B Hoffman; Franz H Messerli; Deepak L Bhatt
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

9.  Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era.

Authors:  Daisaku Nakatani; Yasuhiko Sakata; Shinichiro Suna; Masaya Usami; Sen Matsumoto; Masahiko Shimizu; Masahiko Hara; Masaaki Uematsu; Masatake Fukunami; Toshimitsu Hamasaki; Hiroshi Sato; Masatsugu Hori; Issei Komuro
Journal:  Am J Cardiol       Date:  2012-12-08       Impact factor: 2.778

10.  Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty?

Authors:  Steven J Kernis; Kishore J Harjai; Gregg W Stone; Lorelei L Grines; Judith A Boura; William W O'Neill; Cindy L Grines
Journal:  J Am Coll Cardiol       Date:  2004-05-19       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.